Grifols, S.A. (NASDAQ:GRFS) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC grew its position in Grifols, S.A. (NASDAQ:GRFS) by 28.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,866 shares of the biotechnology company’s stock after purchasing an additional 3,936 shares during the period. HighTower Advisors LLC’s holdings in Grifols were worth $133,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of GRFS. Whitebox Advisors LLC lifted its position in Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after buying an additional 1,519,093 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Grifols by 144.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after acquiring an additional 1,181,959 shares during the period. Highland Peak Capital LLC lifted its holdings in shares of Grifols by 29.5% during the 4th quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company’s stock valued at $5,849,000 after acquiring an additional 179,114 shares in the last quarter. Barclays PLC boosted its position in Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 469,401 shares during the period. Finally, Stifel Financial Corp acquired a new stake in Grifols in the 3rd quarter valued at $1,043,000.

Grifols Stock Down 6.5 %

NASDAQ GRFS opened at $6.65 on Friday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The business has a 50 day moving average price of $7.53 and a two-hundred day moving average price of $7.98. The stock has a market cap of $4.57 billion, a PE ratio of 5.68 and a beta of 0.35.

Wall Street Analyst Weigh In

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.